Close menu




March 3rd, 2021 | 07:34 CET

Evotec, Cardiol Therapeutics, MorphoSys - Watch out: Great upside potential here in the short term

  • Biotechnology
Photo credits: pixabay.com

In the pandemic, investors have learned that small biotech companies, some still with a start-up character, can be worth billions overnight. BioNTech and CureVac are familiar names from the press. Both are linked by the Corona drug and the fact that they are headquartered in Germany. Two other German companies, Evotec and MorphoSys, have written a good growth story on the stock exchange in recent years: small becomes big! Small is also still the Canadian Cardiol Therapeutics. With the announced dual listing on the US technology exchange Nasdaq, a valuation boost could be imminent.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: CA14161Y2006 , DE0006632003 , DE0005664809

Table of contents:


    EVOTEC SE - Excitement is rising, figures coming at the end of March

    Evotec has shown an impressive performance on the stock market in recent years. In October 2009, the shares were included in the TECDAX at around EUR 2. In 2018 the Company was promoted to the MDAX at quotations of EUR 18. Currently, the Company has a market capitalization of EUR 5.4 billion at around EUR 32. The Hamburg-based drug discovery and development Company works within research alliances and development partnerships with leading pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies to generate and advance innovative approaches to developing new pharmaceutical products. Evotec also has proprietary drug candidates in clinical as well as preclinical development. The Company now employs over 3,000 people worldwide.

    The indicated areas included in the Company's activity field include Alzheimer's disease, diabetes, cancer, and various inflammatory and infectious diseases. The list of development partnerships with pharmaceutical companies is long and includes Bayer, Sanofi, Genentech and AstraZeneca.

    On Monday, "industry colleague" MorphSys published its preliminary figures for the past fiscal year. On March 25, the Hamburg-based Company will present its annual report. A look at the key figures shows impressively that the valuation of Evotec is based on potentials that are not yet measurable today. The 2021 P/E ratio is around 130. The stock belongs on the buy list for long-term investors who want to get involved in the industry.

    CARDIOL THERAPEUTICS INC - On to the Nasdaq with full pockets!

    Canadian biotechnology Company Cardiol Therapeutics, which is working to develop innovative clinical-stage anti-inflammatory therapies for cardiovascular disease treatment, announced two important pieces of information yesterday. The Company has filed for an up-listing of its common stock on Nasdaq. According to the Company, this is a logical step, as the US technology exchange represents the largest relevant stock exchange and has a lot of investor attention. A significant effect, if the application goes through, would undoubtedly be a higher company valuation.

    In addition, Cardiol reported having generated over CAD 10 million from the exercise of warrants and stock options. On the one hand, this strengthens the balance sheet and enables further development steps, e.g., initiating the phase II / III clinical trial program in the US. A study is planned to investigate the cardioprotective properties of the lead product CardiolRx in 422 hospitalized COVID-19 patients with pre-existing conditions or risk factors for cardiovascular disease. Cardiol hopes to publish these results later this year.

    CardiolRx is a pharmaceutically manufactured oral cannabidiol formulation. The objective is to evaluate the efficacy and safety of the compound as a cardioprotective therapy to reduce mortality and serious heart disease in COVID-19 patients with pre-existing cardiovascular disease or risk factors, and to investigate the impact of the compound on key markers of inflammatory heart disease. Thus, exciting times lie ahead for the Company and its shareholders. With a market capitalization of CAD 138 million, the potential of the innovative compound is insufficiently priced.

    MORPHOSYS AG - own forecasts exceeded

    This Monday, the biopharmaceutical Company based in Planegg near Munich published its preliminary figures for the past fiscal year, topping the annual forecast that had only been raised in October. The Company generated an operating profit (EBIT) of EUR 27.4 million, which was well above the forecast range of EUR 10 to 20 million. In the previous year, a loss of around EUR 72 million had to be posted. The sales forecast of around EUR 328 million represents a more than fourfold increase over the previous year's figure. Initial analyst reactions were positive, after which the share price rose briefly but gave up most of the gains.

    MorphoSys has developed many antibody technologies that it uses for both its proprietary and partnered programs. The South German Company's most important asset is a vast antibody library called HuCAL, which contains more than 10 billion human antibodies that scientists use to make human antibodies.

    MorphoSys receives milestone payments on drug development under the partnerships and shares in sales of marketable drugs. Partner companies include major international pharmaceutical companies such as Bayer, Novartis, Johnson & Johnson, Merck & Co, Pfizer and Eli Lilly. Founded in 1992, the Company has impressively demonstrated that a start-up can become an internationally renowned player who is currently weighing in at an impressive EUR 2.8 billion on the stock exchange.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 30th, 2022 | 13:49 CEST

    Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?

    • Biotechnology

    Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?

    Read

    Commented by Stefan Feulner on June 27th, 2022 | 12:12 CEST

    BrainChip and Palantir with strong rebound - How does BioNTech react?

    • chips
    • Technology
    • Biotechnology

    The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.

    Read

    Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST

    Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?

    • Biotechnology
    • Pharma

    Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.

    Read